Evaluation of pharmacogenomics and hepatic nuclear imaging-related covariates by population pharmacokinetic models of irinotecan and its metabolites.
Saved in:
| Title: | Evaluation of pharmacogenomics and hepatic nuclear imaging-related covariates by population pharmacokinetic models of irinotecan and its metabolites. |
|---|---|
| Authors: | Liu Z; School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia.; Clinical Pharmacology, Department of Medicine, The Royal Children's Hospital Melbourne, Melbourne, Australia.; Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia., Martin JH; School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia., Liauw W; Department of Medical Oncology, St. George's Hospital, Sydney, Australia., McLachlan SA; Department of Medical Oncology, St. Vincent's Hospital, Melbourne, Australia., Link E; Biostatistics and Clinical Trials Centre, Peter MacCallum Cancer Centre, Melbourne, Australia.; Department of Oncology, Sir Peter MacCallum, University of Melbourne, Melbourne, Australia., Matera A; Biostatistics and Clinical Trials Centre, Peter MacCallum Cancer Centre, Melbourne, Australia., Thompson M; Department of Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia., Jefford M; Department of Oncology, Sir Peter MacCallum, University of Melbourne, Melbourne, Australia.; Department of Medical Oncology, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC, 3000, Australia., Hicks RJ; Department of Oncology, Sir Peter MacCallum, University of Melbourne, Melbourne, Australia.; Department of Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia., Cullinane C; Department of Oncology, Sir Peter MacCallum, University of Melbourne, Melbourne, Australia.; Translational Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia., Hatzimihalis A; Translational Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia., Campbell I; Department of Oncology, Sir Peter MacCallum, University of Melbourne, Melbourne, Australia.; Victorian Breast Cancer Research Cooperative (VBCRC) Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia., Crowley S; Previously Victorian Breast Cancer Research Cooperative (VBCRC) Cancer Genetics Laboratory, The Murdoch Children's Research Institute, The Royal Children's Hospital, Peter MacCallum Cancer Centre), MelbourneMelbourne, Australia., Beale PJ; Department of Medical Oncology, Concord and Royal Prince Alfred Hospital, Sydney, Australia., Karapetis CS; Department of Medical Oncology, Flinders Medical Centre, Flinders Centre for Innovation in Cancer, Adelaide, Australia., Price T; Department of Medical Oncology, The Queen Elizabeth Hospital, Adelaide, Australia., Burge ME; Department of Medical Oncology, Royal Brisbane and Women's Hospital, Brisbane, Australia., Michael M; Department of Oncology, Sir Peter MacCallum, University of Melbourne, Melbourne, Australia. Michael.Michael@petermac.org.; Department of Medical Oncology, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC, 3000, Australia. Michael.Michael@petermac.org. |
| Source: | European journal of clinical pharmacology [Eur J Clin Pharmacol] 2022 Jan; Vol. 78 (1), pp. 53-64. Date of Electronic Publication: 2021 Sep 04. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Country of Publication: Germany NLM ID: 1256165 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1041 (Electronic) Linking ISSN: 00316970 NLM ISO Abbreviation: Eur J Clin Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-1041 |
|---|---|
| DOI: | 10.1007/s00228-021-03206-w |
